Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Japanese Journal of Radiology
Published in: Japanese Journal of Radiology 9/2018

01-09-2018 | Original Article

Radiofrequency ablation versus cryoablation for T1b renal cell carcinoma: a multi-center study

Authors: Takaaki Hasegawa, Takashi Yamanaka, Hideo Gobara, Masaya Miyazaki, Haruyuki Takaki, Yozo Sato, Yoshitaka Inaba, Koichiro Yamakado

Published in: Japanese Journal of Radiology | Issue 9/2018

Login to get access

Abstract

Purpose

To compare the clinical outcomes between radiofrequency ablation (RFA) and cryoablation for the treatment of clinical T1b (cT1b) renal cell carcinoma (RCC).

Materials and methods

The data of 46 patients [(39 men and 7 women, median age; 73 years, range 39–87 years)] were gathered from 3 institutions. RFA and cryoablation were performed on 23 patients each. The median number of ablation needle was 2 (range 1–4) and 4 (range 3–5, p < 0.0001) in RFA and cryoablation, respectively. Technique efficacy defined as coverage of the tumor by ablative zone, adverse events, local tumor progression, and survival were compared between the RFA and cryoablation groups.

Results

The primary technique efficacy rate was significantly higher in the cryoablation group (96%, 22/23) than in the RFA group (65%, 15/23, P = 0.02). There was no significant difference in the secondary technique efficacy rate after additional RFA and cryoablation [21/23 (91%) vs. 23/23 (100%); P = 0.24]. The incidence of grade 3 or higher adverse events was similar between the 2 groups (P > 0.99). There was no significant difference between local tumor progression rate after RFA and cryoablation [3/21 (14%) vs. 2/23 (9%); P = 0.66]. The 5-year overall survival rates were comparable between RFA and cryoablation (78 vs. 82%; P =0.82).

Conclusion

Other than primary technique efficacy, the clinical outcomes between RFA and cryoablation were similar in patients with cT1b RCC.
Literature
1.
Smaldone MC, Egleston B, Hollingsworth JM, Hollenbeck BK, Miller DC, Morgan TM, et al. Understanding treatment disconnect and mortality trends in renal cell carcinoma using tumor registry data. Med Care. 2017;55(4):398–404.CrossRefPubMedPubMedCentral
2.
Cooperberg MR, Mallin K, Ritchey J, Villalta JD, Carroll PR, Kane CJ. Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the national cancer data base, 1993–2004. J Urol. 2008;179:2131–5.CrossRefPubMed
3.
Gudmundsson E, Hellborg H, Lundstam S, Erikson S, Ljungberg B. Metastatic potential in renal cell carcinomas < 7 cm: Swedish kidney cancer quality register data. Eur Urol. 2011;60(5):975–82.CrossRef
4.
Zhang C, Li X, Hao H, Yu W, He Z, Zhou L. The correlation between size of renal cell carcinoma and its histopathological characteristics: a single center study of 1867 renal cell carcinoma cases. BJU Int. 2012;110((11 Pt B)):E481–5.CrossRefPubMed
5.
Baillargeon-Gagne S, Jeldres C, Lughezzani G, Sun M, Isbarn H, Capitanio U, et al. A comparative population-based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinoma. BJU Int. 2010;105(3):359–64.CrossRefPubMed
6.
Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–24.CrossRefPubMed
7.
Campbell S, Uzzo RG, Allaf ME, Bass EB, Cadeddu JA, Chang A, et al. Renal mass and localized renal cancer: AUA guideline. J Urol. 2017;198(3):520–9.CrossRefPubMed
8.
Mimura H, Arai Y, Yamakado K, Sone M, Takeuchi Y, Miki T, et al. Phase I/II study of radiofrequency ablation for malignant renal tumors: Japan interventional radiology in oncology study group 0701. Cardiovasc Intervent Radiol. 2016;39(5):717–23.CrossRefPubMed
9.
Takaki H, Yamakado K, Soga N, Arima K, Nakatsuka A, Kashima M, et al. Midterm results of radiofrequency ablation versus nephrectomy for T1a renal cell carcinoma. Jpn J Radiol. 2010;28(6):460–8.CrossRefPubMed
10.
Uhlig A, Hahn O, Strauss A, Lotz J, Trojan L, Müller-Wille R, et al. Treatment for localized T1a clear cell renal cell carcinoma: survival benefit for cryosurgery and thermal ablation compared to deferred therapy. Cardiovasc Intervent Radiol. 2018;41(2):277–83.CrossRefPubMed
11.
Zargar H, Samarasekera D, Khalifeh A, Remer EM, O’Malley C, Akca O, et al. Laparoscopic vs percutaneous cryoablation for the small renal mass: 15-year experience at a single center. Urology. 2015;85(4):850–5.CrossRefPubMed
12.
Iannuccilli JD, Dupuy DE, Beland MD, Machan JT, Golijanin DJ, Mayo-Smith WW. Effectiveness and safety of computed tomography-guided radiofrequency ablation of renal cancer: a 14-year single institution experience in 203 patients. Eur Radiol. 2016;26(6):1656–64.CrossRefPubMed
13.
Pantelidou M, Challacombe B, McGrath A, Brown M, Ilyas S, Katsanos K, et al. Percutaneous radiofrequency ablation versus robotic-assisted partial nephrectomy for the treatment of small renal cell carcinoma. Cardiovasc Intervent Radiol. 2016;39(11):1595–603.CrossRefPubMedPubMedCentral
14.
Schmit GD, Thompson RH, Kurup AN, Weisbrod AJ, Carter RE, Callstrom MR, et al. Percutaneous cryoablation of solitary sporadic renal cell carcinomas. BJU Int. 2012;110((11 Pt B)):E526–31.CrossRefPubMed
15.
Psutka SP, Feldman AS, McDougal WS, McGovern FJ, Mueller P, Gervais DA. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma. Eur Urol. 2013;63(3):486–92.CrossRefPubMed
16.
Atwell TD, Vlaminck JJ, Boorjian SA, Kurup AN, Callstrom MR, Weisbrod AJ, et al. Percutaneous cryoablation of stage T1b renal cell carcinoma: technique considerations, safety, and local tumor control. J Vasc Interv Radiol. 2015;26(6):792–9.CrossRefPubMed
17.
Caputo PA, Zargar H, Ramirez D, Andrade HS, Akca O, Gao T, et al. Cryoablation versus partial nephrectomy for clinical T1b renal tumors: a matched group comparative analysis. Eur Urol. 2017;71(1):111–7.CrossRefPubMed
18.
Takaki H, Soga N, Kanda H, Nakatsuka A, Uraki J, Fujimori M, et al. Radiofrequency ablation versus radical nephrectomy: clinical outcomes for stage T1b renal cell carcinoma. Radiology. 2014;270(1):292–9.CrossRefPubMed
19.
Chang X, Liu T, Zhang F, Ji C, Zhao X, Wang W, et al. Radiofrequency ablation versus partial nephrectomy for clinical T1b renal-cell carcinoma: long-term clinical and oncologic outcomes based on a propensity score analysis. J Endourol. 2015;29(5):518–25.CrossRefPubMed
20.
D’Andrea D, Shariat SF, Klatte T. Update on ablative therapies of renal tumors. Curr Opin Urol. 2016;26(5):410–6.CrossRefPubMed
21.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649–55.CrossRefPubMed
22.
Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR. Renal cell carcinoma: clinical experience and technical success with radio-frequency ablation of 42 tumors. Radiology. 2003;226(2):417–24.CrossRefPubMed
23.
DeBenedectis CM, Beland MD, Dupuy DE, Mayo-Smith WW. Utility of iodinated contrast medium in hydrodissection fluid when performing renal tumor ablation. J Vasc Interv Radiol. 2010;21(5):745–7.CrossRefPubMed
24.
Jinzaki M, Tanimoto A, Mukai M, Ikeda E, Kobayashi S, Yuasa Y, et al. Double-phase helical CT of small renal parenchymal neoplasms: correlation with pathologic findings and tumor angiogenesis. J Comput Assist Tomogr. 2000;24(6):835–42.CrossRefPubMed
25.
Ho VB, Allen SF, Hood MN, Choyke PL. Renal masses: quantitative assessment of enhancement with dynamic MR imaging. Radiology. 2002;224(3):695–700.CrossRefPubMed
26.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130(6):461–70.CrossRefPubMed
27.
Young JR, Margolis D, Sauk S, Pantuck AJ, Sayre J, Raman SS. Clear cell renal cell carcinoma: discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT. Radiology. 2013;267(2):444–53.CrossRefPubMed
28.
Lee HJ, Chung HJ, Wang HK, Shen SH, Chang YH, Chen CK, et al. Evolutionary magnetic resonance appearance of renal cell carcinoma after percutaneous cryoablation. Br J Radiol. 1065;2016(89):20160151.
29.
Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria—a 10-year update. Radiology. 2014;273(1):241–60.CrossRefPubMed
30.
31.
Weight CJ, Larson BT, Gao T, Campbell SC, Lane BR, Kaouk JH, et al. Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival. Urology. 2010;76(3):631–7.CrossRefPubMed
32.
Iizuka J, Kondo T, Hashimoto Y, Kobayashi H, Ikezawa E, Takagi T, et al. Similar functional outcomes after partial nephrectomy for clinical T1b and T1a renal cell carcinoma. Int J Urol. 2012;19(11):980–6.CrossRefPubMed
33.
Jang HA, Kim JW, Byun SS, Hong SH, Kim YJ, Park YH, et al. Oncologic and functional outcomes after partial nephrectomy versus radical nephrectomy in T1b renal cell carcinoma: a multicenter, matched case-control study in Korean patients. Cancer Res Treat. 2016;48(2):612–20.CrossRefPubMed
34.
Simmons MN, Weight CJ, Gill IS. Laparoscopic radical versus partial nephrectomy for tumors > 4 cm: intermediate-term oncologic and functional outcomes. Urology. 2009;73(5):1077–82.CrossRefPubMed
35.
Simmons MN, Chung BI, Gill IS. Perioperative efficacy of laparoscopic partial nephrectomy for tumors larger than 4 cm. Eur Urol. 2009;55(1):199–207.CrossRefPubMed
36.
Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer. 2008;113(10):2671–80.CrossRefPubMed
Metadata
Title
Radiofrequency ablation versus cryoablation for T1b renal cell carcinoma: a multi-center study
Authors
Takaaki Hasegawa
Takashi Yamanaka
Hideo Gobara
Masaya Miyazaki
Haruyuki Takaki
Yozo Sato
Yoshitaka Inaba
Koichiro Yamakado
Publication date
01-09-2018
Publisher
Springer Japan
Published in
Japanese Journal of Radiology / Issue 9/2018
Print ISSN: 1867-1071
Electronic ISSN: 1867-108X
DOI
https://doi.org/10.1007/s11604-018-0756-x

Other articles of this Issue 9/2018

Japanese Journal of Radiology 9/2018 Go to the issue

Review

Imaging findings in radiation therapy complications of the central nervous system

Original Article

99mTc-GSA SPECT/CT fusion imaging for hepatectomy candidates with extremely deteriorated ICG value

Original Article

Denoising of 3D magnetic resonance images with multi-channel residual learning of convolutional neural network

Original Article

18F-FDG PET/CT can predict chemosensitivity and proliferation of epithelial ovarian cancer via SUVmax value

Original Article

Simple quantification of paracardial and epicardial fat dimensions at low-dose chest CT: correlation with metabolic risk factors and usefulness in predicting metabolic syndrome

Original Article

Normal liver tissue change after proton beam therapy